Kelsey Pan, MD, MPH, highlights the utilization of tarlatamab in real-world patients with SCLC ineligible for the phase 2 DeLLphi-301 trial.
Kelsey Pan, MD, MPH
Advertisement
Kelsey Pan, MD, MPH, is the chief hematology/oncology fellow at MD Anderson Cancer Center.
Articles by Kelsey Pan, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
2
FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced Solid Tumors
3
Research Rewind: Phase 3 Breast Cancer Data Highlights From Q2 2026
4
FDA Grants Fast Track Designation to SOT109 in Advanced Colorectal Cancer
5